lipoxin a4 has been researched along with Alveolitis, Fibrosing in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, J; Han, SY; Kim, H; Kim, JM; Lee, YS; Park, SH | 1 |
| Benjamim, CF; Canetti, C; e Silva, PM; Farias-Filho, FA; Ferreira, TP; Fierro, IM; Hogaboam, CM; Kunkel, SL; Martins, V; Molinaro, R; Simões, RL; Valença, SS | 1 |
2 other study(ies) available for lipoxin a4 and Alveolitis, Fibrosing
| Article | Year |
|---|---|
LXA
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Fibrosis; Humans; Lipoxins; Lung; Male; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Radiation; Radiotherapy; Receptor Cross-Talk; Receptors, Formyl Peptide; Receptors, Lipoxin; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2020 |
ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Aspirin; Bleomycin; Immunity, Innate; Lipoxins; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Respiratory Function Tests; Survival Analysis | 2009 |